Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials.
We reviewed the bibliographic evidence from comparative trials regarding the role of rifampin as adjuvant treatment in the treatment of Gram-positive infections [PubMed (1/1950-7/2006)]. Only studies reporting comparative outcome data in patients treated with an antibiotic regimen with the addition or not of rifampin were included. Eight comparative studies were identified [all were randomized controlled trials (RCTs)], five reporting on infections caused by staphylococci (S. aureus in 97% of patients) and three by streptococci. There was no statistically significant difference in mortality between the treatment arms (with and without rifampin) in any of the included studies. Clinical cure was achieved more commonly (p < 0.05) in the rifampin treatment arm in 3/8 studies; in staphylococcal infections of orthopedic stable implants and in beta-hemolytic streptococcal pharyngitis in children (one RCT each), and in one RCT that reported on patients with various staphylococcal infections. However, no statistically significant difference in cure of the infection between the two groups was found after pooling data from two RCTs (121 patients) that reported on patients with various staphylococcal infections (odds ratio = 0.57; 95% confidence interval 0.27-1.17). No differences were noted between the two groups regarding relapse of infection or adverse events. There is only limited evidence from comparative trials regarding the role of rifampin as adjuvant therapeutic agent for infections caused by Gram-positive bacteria, not allowing for definitive conclusions on this important management question. More controlled trials are necessary for better evaluation of this practice.
Bliziotis
I A
IA
Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, Marousi, Athens, Greece.
Ntziora
F
F
Lawrence
K R
KR
Falagas
M E
ME
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D012293:Rifampin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D012293:Rifampin
J Antimicrob Chemother. 2004 Dec;54(6):971-81
15546974
Arch Orthop Trauma Surg. 2001 May;121(5):297-9
11409564
Chemotherapy. 1981;27(5):368-402
7021080
J Pediatr. 1985 Mar;106(3):481-6
3919171
Science. 1999 May 21;284(5418):1318-22
10334980
J Antimicrob Chemother. 2006 Apr;57(4):589-608
16507559
Antimicrob Agents Chemother. 1985 Oct;28(4):467-72
3907494
JAMA. 1978 Aug 25;240(8):751-3
671704
Chemotherapy. 2003 Jul;49(4):189-93
12886054
Circulation. 2005 Jun 14;111(23):e394-434
15956145
South Med J. 1986 Aug;79(8):947-51
3526570
Antimicrob Agents Chemother. 1992 Mar;36(3):620-5
1622173
Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S538-42
6556710
Am J Med Sci. 1984 May-Jun;287(3):49-54
6563847
Antimicrob Agents Chemother. 2002 Mar;46(3):900-3
11850284
Antimicrob Agents Chemother. 2006 Jan;50(1):55-61
16377667
J Am Acad Dermatol. 1992 Mar;26(3 Pt 2):458-61
1564153
J Antimicrob Chemother. 1994 Jul;34(1):189-90
7961212
Ann Intern Med. 1991 Nov 1;115(9):674-80
1929035
Clin Ther. 1991 Nov-Dec;13(6):699-706
1790545
J Pediatr. 1985 Jun;106(6):876-80
3889257
Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S543-8
6556711
Clin Microbiol Infect. 2004 Aug;10(8):765-8
15301684
JAMA. 1998 May 20;279(19):1537-41
9605897
Antimicrob Agents Chemother. 1995 Sep;39(9):1988-92
8540704
Nephrol Dial Transplant. 2006 Sep;21(9):2536-42
16705024
JAMA. 1978 Oct 27;240(18):1963-5
249793
J Antimicrob Chemother. 2006 Apr;57(4):639-47
16501057
Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S515-22
6356280
J Infect Dis. 1985 Jan;151(1):157-65
3965588